Sacubitril-valsartan
Sacubitril-valsartan is a pharmaceutical drug with 62 clinical trials. Currently 9 active trials ongoing. Historical success rate of 93.3%.
Success Metrics
Based on 28 completed trials
Phase Distribution
Phase Distribution
2
Early Stage
9
Mid Stage
30
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
77.8%
28 of 36 finished
22.2%
8 ended early
9
trials recruiting
62
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Sacubitril-valsartan in Patients With Heart Failure.
Hemodynamic Effects of ARNI on Noninvasive Pressure-volume Analysis in Patients With Chronic Heart Failure
Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction
Clinical Trials (62)
Sacubitril-valsartan in Patients With Heart Failure.
Hemodynamic Effects of ARNI on Noninvasive Pressure-volume Analysis in Patients With Chronic Heart Failure
Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction
Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation
A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure
Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation
Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation
Initiation of ARNi and SGLT2i in Patients With HFrEF
Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC
A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study
Enhancing the Natriuretic Peptide System in HFpEF
Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction
Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease
Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF
Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM)
Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)
Sacubitril/Valsartan in Resistant Hypertension
Prevention of Cardiac Dysfunction During Breast Cancer Therapy
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 62